Browsing by Author Zhou, Caicun

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 20 of 26 next >
Issue Date Title Author(s)
2011 A 3-DAY ORAL APREPITANT REGIMEN PROVIDES SUPERIOR PREVENTION OF CINV OVER STANDARD THERAPY IN CHINESE PATIENTS RECEIVING HIGH-DOSE CISPLATIN Zhang, Li;Cheng, Ying;Zhang, Hong-Yu;Zhou, Caicun;Han, Baohui;Zhang, Yiping;Huang, Cheng;Chang, Jianhua;Song, Xiang Q.;Liang, Jun;Liang, Houjie;Bai, Chunxue;Yu, Shiying;Chen, Jia;Wang, Jie;Pan, Hongming;Carides, Alexandra;Chitkara, Denesh
2018 Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung Lu, Shun;Li, Wei;Zhou, Caicun;Hu, Cheng-Ping;Qin, Shukui;Cheng, Gang;Feng, Jifeng;Wang, Jie;Cseh, Agnieszka;Peil, Barbara;Gibson, Neil;Ehrnrooth, Eva;Zhang, Li
2019 Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors Wang, Yuetong;Zhang, Jian;Ren, Shengxiang;Sun, Dan;Huang, Hsin-Yi;Wang, Hua;Jin, Yujuan;Li, Fuming;Zheng, Chao;Yang, Liu;Deng, Lei;Jiang, Zhonglin;Jiang, Tao;Han, Xiangkun;Hou, Shenda;Guo, Chenchen;Li, Fei;Gao, Dong;Qin, Jun;Gao, Daming;Chen, Luonan;Lin, Shu-Hai;Wong, Kwok-Kin;Li, Cheng;Hu, Liang;Zhou, Caicun;Ji, Hongbin
Feb-2021 Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial Fan, Yun;Zhao, Jun;Wang, Qiming;Huang, Dingzhi;Li, Xingya;Chen, Jianhua;Fang, Yong;Duan, Jianchun;Zhou, Caicun;Hu, Yanping;Yang, Haihua;Hu, Yi;Zhou, Jianying;Lin, Xiaoyan;Wang, Lifeng;Wang, Zhijie;Xu, Yanjun;Zhang, Tao;Shi, Wei;Zou, Jianjun;Wang, Jie
Aug-2020 Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial Wang, Jie;Fan, Yun;Zhao, Jun;Wang, Qiming;Huang, Dingzhi;Li, Xingya;Chen, Jianhua;Fang, Yong;Wang, Zhijie;Zhou, Caicun;Hu, Yanping;Yang, Haihua;Hu, Yi;Zhou, Jianying;Lin, Xiaoyan;Wang, Lifeng;Xu, Yanjun;Li, Hanying
Mar-2021 Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Zhou, Caicun;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, LiZhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, QiMing;Cheng, Ying;Wu, Fengying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, XiaoRong;Zhang, Tao;Shi, Wei;Zou, Jianjun
2017 A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel Wu, Yi-Long;Wang, Chang-Li;Sun, Yan;Liao, Mei-Lin;Guan, Zhong-Zhen;Yang, Zhi-Min;Zhou, Qing-Hua;Lu, Shun;Cheng, Ying;Liu, Xiao-Qing;Zhang, Xu-Chao;Zhou, Caicun;Wang, Jie;Zhou, Qing;Song, Yong;Han, Bao-Hui;Ma, Zhi-Yong;Yang, Fan;Wang, Qun;Chuai, Shao-Kun;Shao, Yang;He, Wei;Zhu, Guanshan;Xiong, Lei;Wang, Jian-Jun;Chen, Ke-Neng;Zhang, Li;Mao, Wei-Min;Ma, Sheng-Lin;Feng, Ji-Feng;Yang, Xue-Ning;Xu, Lin;Chen, Gang;Zhao, Jian;Song, Qi-Bin;Shen-Tu, Yang;Qiao, Gui-Bin;Yu, Ding;Yu, Shi-Ying;Hu, Yi;Chen, Ming;Chen, Go
2018 Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial Wang, Zhijie;Cheng, Ying;An, Tongtong;Gao, Hongjun;Wang, Kai;Zhou, Qing;Hu, Yanping;Song, Yong;Ding, Cuimin;Peng, Feng;Liang, Li;Hu, Yi;Huang, Cheng;Zhou, Caicun;Shi, Yuankai;Zhang, Li;Ye, Xin;Zhang, Meizhuo;Chuai, Shaokun;Zhu, Guanshan;Hu, Jin;Wu, Yi-long;Wang, Jie
2011 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Zhou, Caicun;Wu, Yi-Long;Chen, Gongyan;Feng, Jifeng;Liu, Xiao-Qing;Wang, Changli;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Chengping;Hu, Chunhong;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu;Ma, Jun;Zhang, Li;You, Changxuan
20-May-2020 Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia. Matsumoto, Shingo;Zhou, Caicun;Kuo, Chih-Hsi;Yoh, Kiyotaka;Kato, Terufumi;Nishino, Kazumi;Furuya, Naoki;Zhang, Shucai;Lin, Dongmei;Han, Yuchen;Wang, Chin-Chou;Ikeda, Takaya;Zenke, Yoshitaka;Goto, Koichi
2015 Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma Cai, Weijing;Lin, Dongmei;Wu, Chunyan;Li, Xuefei;Zhao, Chao;Zheng, Limou;Chuai, Shannon;Fei, Ke;Zhou, Caicun;Hirsch, Fred R.
Nov-2022 Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy Wu, Fengying;Jiang, Tao;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, Lizhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, Qiming;Cheng, Ying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, Xiaorong;Zhang, Tao;Shi, Wei;Zou, Jianjun;Bai, Xuejuan;Ren, Shengxiang;Zhou, Caicun
2015 An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei
2015 An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei
Jul-2021 ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). Shi, Yuankai;Wu, Lin;Yu, Xinmin;Wang, Yan;Xing, Puyuan;Zhou, Jianying;Wang, Airong;Shi, Jianhua;Hu, Yi;Wang, Ziping;An, Guangyu;Fang, Yong;Sun, Sanyuan;Zhou, Caicun;Wang, Changli;Ye, Feng;Li, Xingya;Wang, Junye;Wang, Mengzhao;Liu, Yunpeng;Zhao, Yanqiu;Feng, Jifeng
2012 Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCL Zhou, Caicun;Wu, Yi Long;Liu, Xiaoqing;Wang, Changli;Chen, Gongyan;Feng, Ji Feng;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Cheng-ping;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu
2016 Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer Xu, Naiqing;Fang, Wenfeng;Mu, Libing;Tang, Yanna;Gao, Lei;Ren, Shengxiang;Cao, Dengfeng;Zhou, Lixin;Zhang, Aiqun;Liu, Deruo;Zhou, Caicun;Wong, Kwok-Kin;Yu, Lei;Zhang, Li;Chen, Liang
Apr-2021 A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer Yang, Jin-Ji;Fang, Jian;Shu, Yong-Qian;Chang, Jian-Hua;Chen, Gong-Yan;He, Jian Xing;Li, Wei;Liu, Xiao-Qing;Yang, Nong;Zhou, Caicun;Huang, Jian An;Frigault, Melanie M.;Hartmaier, Ryan;Ahmed, Ghada F.;Egile, Coumaran;Morgan, Shethah;Verheijen, Remy B.;Mellemgaard, Anders;Yang, Liu;Wu, Yi-Long
Jan-2022 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China Tu, Hai-Yan;Feng, Jifeng;Shi, Meiqi;Zhao, Jun;Wang, Yuyan;Chang, Jianhua;Wang, Jialei;Cheng, Ying;Zhu, Jing;Tan, Eng-Huat;Li, Kai;Zhang, Yiping;Lee, Victor;Yang, Cheng-Ta;Su, Wu-Chou;Lam, David Chi-Leung;Srinivasa, B. J.;Rajappa, Senthil;Ho, Ching-Liang;Lam, Kwok Chi;Hu, Yi;Bondarde, Shailesh Arjun;Liu, Xiaoqing;Tian, Yahui;Xue, Zhiyi;Cseh, Agnieszka;Huang, Dennis Chin-Lun;Zhou, Caicun;Wu, Yi-Long
2018 Prognostic value of PD-L1 expression in combination with CD8(+) TILs density in patients with surgically resected non-small cell lung cancer Yang, Hui;Shi, Jinpeng;Lin, Dongmei;Li, Xuefei;Zhao, Chao;Wang, Qi;Zhang, Limin;Jiang, Tao;Zhao, Sha;Liu, Xiaozhen;Jia, Yijun;Zhang, Yajun;Cai, Weijing;Zhou, Caicun
Showing results 1 to 20 of 26 next >